Compare HSBC Holdings plc (HSBC) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs Sana Biotechnology Inc — how do they compare? HSBC Holdings plc trades at $104.82 (market cap $353.82B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: HSBC Holdings plc is far larger — about 313.1× Sana Biotechnology Inc's market cap, and HSBC Holdings plc pays a 3.63% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| HSBC | SANA | |
|---|---|---|
Market Cap | $353.82B | $1.13B |
Sector | Technology | Health |
52-Week High | $107.86 | $5.92 |
52-Week Low | $63.84 | $2.68 |
Dividend Yield | 3.63% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $104.12, up 0.77% today, with a bullish technical signal from moving averages and support near $103. The bank reported strong Q2 2026 results with a 7% revenue increase and a $1 billion buyback, while net income margin improved to 34.54% in 2026. Analyst sentiment is mixed, with 38.1% buy ratings, but recent news includes a Citi downgrade citing a 40% stock run-up.
The outlook remains positive due to earnings momentum and shareholder returns, but risks include China regulatory changes and valuation concerns after the recent rally. Further upside depends on sustained revenue growth and effective capital allocation.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
